Press release
Alpha-1 Antitrypsin Deficiency (AATD) Market New Product Development & Latest Trends
IntroductionAlpha-1 antitrypsin deficiency (AATD) is a rare genetic disorder caused by mutations in the SERPINA1 gene, leading to low levels of the alpha-1 antitrypsin (AAT) protein. This protein normally protects the lungs from neutrophil elastase; deficiency results in early-onset chronic obstructive pulmonary disease (COPD), emphysema, and liver disease.
Despite affecting an estimated 1 in 2,500-5,000 people of European descent, AATD is significantly underdiagnosed due to overlapping symptoms with asthma and COPD. However, growing awareness, advanced diagnostic techniques, and emerging therapies are transforming the AATD market. Expanding augmentation therapies, gene therapies, and novel biologics are fueling optimism for patients and healthcare providers.
Download Full PDF Sample Copy of Market Report @
https://exactitudeconsultancy.com/request-sample/71646
Market Overview
The global alpha-1 antitrypsin deficiency (AATD) market was valued at USD 1.6 billion in 2024 and is projected to reach USD 3.4 billion by 2034, growing at a CAGR of 7.6% during the forecast period.
Key Highlights:
• Rising prevalence and improved genetic testing fueling earlier diagnoses.
• Increasing adoption of augmentation therapy as the current standard of care.
• Expanding pipeline of gene therapies aiming for long-term correction.
• Growing global awareness programs and rare disease policy frameworks.
Segmentation Analysis
By Therapy Type
• Augmentation therapy (plasma-derived AAT replacement)
• Gene therapy (in development)
• RNA interference (RNAi) therapies (pipeline)
• Supportive therapies (bronchodilators, corticosteroids)
• Liver transplantation and supportive hepatology care
By Route of Administration
• Intravenous (standard augmentation therapy)
• Inhaled (investigational therapies)
• Oral (emerging drug candidates)
By Patient Group
• Pulmonary AATD patients
• Hepatic AATD patients
• Pediatric population
• Adults/elderly
By End-User
• Hospitals
• Specialty clinics (pulmonology, hepatology)
• Ambulatory care centers
• Research institutes
Segmentation Summary:
Augmentation therapy dominates today's market, but gene therapy and RNAi therapeutics represent the most promising future segments. Hospitals and specialty clinics remain the leading end-users, given the need for regular intravenous infusions and multidisciplinary care.
Explore Full Report here:
https://exactitudeconsultancy.com/reports/71646/alpha-1-antitrypsin-deficiency-market
Regional Analysis
North America
• Largest market, with the U.S. leading due to advanced diagnostics, established augmentation therapy adoption, and strong rare disease advocacy.
• Multiple gene therapy clinical trials underway.
Europe
• Significant share, supported by government rare disease initiatives and reimbursement systems for augmentation therapy.
• Germany, France, and the UK drive regional growth.
Asia-Pacific
• Fastest-growing region due to rising healthcare access, growing prevalence awareness, and expanding rare disease programs.
• Japan, China, and India are emerging as important contributors.
Middle East & Africa
• Smaller market, but improving healthcare infrastructure and rare disease awareness are supporting gradual adoption.
Latin America
• Brazil and Mexico lead regional growth with expanding healthcare reforms and rare disease support.
Regional Summary:
North America and Europe dominate due to established therapy frameworks and strong advocacy, while Asia-Pacific will record the fastest CAGR through 2034, reflecting demographic expansion, policy adoption, and rising diagnostics.
Market Dynamics
Key Growth Drivers
• Rising prevalence and underdiagnosis correction through better screening.
• Increasing adoption of plasma-derived augmentation therapies.
• Expanding gene therapy pipeline offering curative potential.
• Strong rare disease advocacy and government funding.
Key Challenges
• High treatment costs for augmentation therapy, limiting affordability.
• Limited plasma supply for therapy production.
• Lack of curative therapies - augmentation slows but does not reverse disease progression.
• Regional disparities in diagnosis and treatment availability.
Latest Trends
• Development of longer-acting augmentation therapies to reduce infusion frequency.
• Advancements in gene therapy and RNAi-based therapeutics.
• Growing use of real-world evidence (RWE) to guide treatment optimization.
• Expansion of screening programs for early detection in high-risk populations.
Get Your Exclusive Offer with up to 10% Discount :
https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71646
Competitor Analysis
Leading Market Players
• Grifols, S.A.
• CSL Behring
• Takeda Pharmaceutical Company Limited
• Kamada Ltd.
• Vertex Pharmaceuticals Incorporated
• Arrowhead Pharmaceuticals, Inc.
• Alnylam Pharmaceuticals, Inc.
• AstraZeneca Plc
• GlaxoSmithKline plc
• Intellia Therapeutics, Inc.
Competitive Summary:
The AATD market is moderately consolidated, dominated by Grifols, CSL Behring, and Takeda in augmentation therapies. Biotech innovators like Vertex, Arrowhead, and Alnylam are advancing gene and RNAi therapies. Strategic collaborations, licensing deals, and investments in plasma supply chains are central to maintaining competitiveness.
Conclusion
The alpha-1 antitrypsin deficiency (AATD) market is expected to grow from USD 1.6 billion in 2024 to USD 3.4 billion by 2034, at a healthy CAGR of 7.6%.
Key Takeaways:
• Augmentation therapy remains the gold standard but has limitations.
• Gene therapy and RNAi therapeutics represent the next frontier of innovation.
• North America and Europe dominate today, while Asia-Pacific will grow fastest.
• High costs, plasma supply shortages, and limited awareness remain challenges.
This report is also available in the following languages : Japanese (アルファ1アンチトリプシン欠乏症市場), Korean (알파-1 항트립신 결핍증 시장), Chinese (Alpha-1 抗胰蛋白酶缺乏症市场), French (Marché du déficit en alpha-1 antitrypsine), German (Markt für Alpha-1-Antitrypsin-Mangel), and Italian (Mercato della carenza di alfa-1 antitripsina), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @
https://exactitudeconsultancy.com/request-sample/71646
Our More Reports:
Next Generation Sequencing Services Market
https://exactitudeconsultancy.com/reports/72395/next-generation-sequencing-services-market
Meditation Market
https://exactitudeconsultancy.com/reports/72394/meditation-market
DNA Vaccine Market
https://exactitudeconsultancy.com/reports/72393/dna-vaccine-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
IRFAN TAMBOLI
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Alpha-1 Antitrypsin Deficiency (AATD) Market New Product Development & Latest Trends here
News-ID: 4173960 • Views: …
More Releases from Exactitude Consultancy

Hypertrophic Cardiomyopathy Market to Reach USD 3.21 Billion by 2034, Growing at …
Introduction
Hypertrophic cardiomyopathy (HCM) is a genetic heart disorder characterized by abnormal thickening of the heart muscle, which can impair blood flow and increase the risk of arrhythmias, heart failure, and sudden cardiac death. Once managed primarily through beta-blockers, calcium channel blockers, and invasive procedures, the HCM treatment landscape has expanded with the approval of targeted therapies such as cardiac myosin inhibitors.
Growing awareness of genetic cardiovascular diseases, advances in molecular diagnostics,…

Biologics Contract Research Organization (CRO) Market to Reach USD 37.9 Billion …
Introduction
Biologics-including monoclonal antibodies, vaccines, recombinant proteins, and advanced therapies-are at the forefront of modern medicine. Their development, however, requires significant expertise, advanced infrastructure, and compliance with stringent regulatory standards. To meet these demands, pharmaceutical and biotechnology companies are increasingly outsourcing to Contract Research Organizations (CROs) specializing in biologics.
Biologics CROs provide services spanning discovery, preclinical research, clinical trials, bioanalytical testing, and regulatory consulting. With the rise of biologics, biosimilars, and advanced…

Niemann-Pick Disease Market to Reach USD 1.02 Billion by 2034, Growing at 10.6% …
Introduction
Niemann-Pick disease (NPD) is a group of rare, inherited lysosomal storage disorders caused by mutations that disrupt lipid metabolism, leading to progressive neurological decline, organ dysfunction, and premature death. The condition is categorized into several subtypes (A, B, and C), each varying in severity and progression.
Historically, treatment has been limited to palliative and supportive care. However, the landscape is changing rapidly with the development of enzyme replacement therapies (ERT), substrate…

PERK Inhibitors Market Forecast: USD 3.2 Billion by 2034 | Major Participants: N …
The fight against cancer and neurodegenerative diseases has brought the spotlight on the PERK (Protein kinase RNA-like endoplasmic reticulum kinase) pathway, a critical regulator of the unfolded protein response. PERK inhibitors are designed to modulate this pathway, reducing stress-induced cell death and playing a pivotal role in oncology, neurodegenerative research, and metabolic disorders. As precision medicine continues to gain traction, PERK inhibitors are attracting significant attention from both biotech firms…
More Releases for AAT
AAT Salt Recognized as the Best Salt Delivery Wisconsin 2025
AAT Salt is thrilled to announce its recognition as the best salt delivery service for Wisconsin homes and businesses [https://aatsalt.com/] by leading industry experts. Designed specifically for residents and businesses seeking hassle-free solutions, AAT Salt has emerged as the go-to provider of high-quality salt delivery and water treatment support across the region.
With nearly a century of experience serving Southeastern Wisconsin (dating back to 1930) AAT Salt stands out in the…
Anytime Anywhere Therapy (AAT): Breaking Barriers to Mental Health Care in Ontar …
Ontario, Canada -February 5, 2025 - Anytime Anywhere Therapy (AAT) is proud to serve individuals, couples, families, children (ages 6+), teenagers, and seniors across Ontario, offering inclusive, accessible, and fully online mental health services. Committed to eliminating barriers to mental health care, AAT provides round-the-clock support with licensed Canadian therapists who specialize in a wide range of therapeutic approaches and treatment areas.
AAT's innovative platform not only benefits clients but also…
Alpha 1-Antitrypsin (AAT) Replacement Therapy Market Global Research and Clinica …
Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market studies the latest industry trends, market development aspects, market gains, and industry scenario during the forecast period. The report provides the details related to fundamental overview, development status, latest advancements, market dominance and market dynamics.
Buy Now This Report at:
https://www.marketinsightsreports.com/report/purchase/071316596?mode=su?source=openpr&Mode=20
The report presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market. Top Companies in the Global…
What's Driving the Wheelchair Stair Climber Market Growth? TopChair, Antano Grou …
UpMarketResearch.com includes new market research report Wheelchair Stair Climber Market to its huge collection of research reports. The Wheelchair Stair Climber Market report presents an all-inclusive approach to the Wheelchair Stair Climber Market growth along with a defined and methodical examination of the overall market. To start with, the report provides better insights of the competitive landscape of the global Wheelchair Stair Climber Market and also puts forth the several…
Wheelchair Stair Climber Market 2017- TopChair, Antano Group, AAT, KSP ITALIA, B …
Wheelchair Stair Climber is an exercise machine on which helps wheel chair go upstairs or downstairs. These machines makes wheelchair climbing the stairs easily. These machines generally have two types, automatic and manual. Manual wheelchair need other people behind the wheel to control the climber while automatic climber can climb the stair by itself. Generally the automatic wheelchair climbers are powered by electricity.
Request for sample(No Cost for sample) @ https://goo.gl/cpG0M9
Major…
Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Industry Analysis (2016-202 …
Researchmoz added Most up-to-date research on "Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020)" to its huge collection of research reports.
The report titled Global Alpha 1-Antitrypsin (AAT) Replacement Therapy Market: Size, Trends and Forecast (2016-2020) provides an in-depth analysis of the global AAT Replacement Therapy market with detailed analysis of market sizing, growth and market share. The report provides market size by value and volume along…